0.005 one sided) but not at 1 year (p 5 0.34, two-sided). There was no significant difference in mortality rates between the EAP group and the control group. Conclusions: Multiple transfusions raise the risk of secondary hemochromatosis, a risk factor for infections and increased mortality. Erythropoietin-assisted phlebotomy is a treatment to prevent the complications of iron overload in HSCT patients. Methods: Randomized, double-blind, placebo-controlled, multicenter Phase I study of a 4-dose ZV HT regimen (1 dose pre-HCT; 3 doses post-HCT, each 30 days apart) in adults $ 18 years with autologous (n 5 50) or allogeneic (n 5 50) HCT. In each group, 40 received ZV HT and 10 placebo (Pbo). Blood was collected at baseline & 28 days after each dose to measure (1) VZV antibody concentrations by glycoprotein enzyme-linked immunosorbent assay (gpELISA), and (2) varicella zoster virus (VZV) T-cell responses by interferon-gamma enzyme-linked immunospot (IFN-g ELI-SPOT) assay. All vaccinated patients were evaluated for adverse events (AEs) through day 28 postdose 4. Immunogenicity analyses for both HCT groups were exploratory (no pre-specified hypotheses). Results: ZV HT safety profile was similar to placebo. Injection-site adverse events (AEs) occurred in 15% of the ZV HT group and 10% of the Pbo group. There were no reported vaccine-related serious AEs. No patients discontinued due to vaccine-related AEs. Herpes zoster (PCR positive) occurred in 1 ZV HT and 1 placebo patient (both autologous HCT patients). There were also 2 patients in the ZV HT group that had suspected HZ not confirmed by PCR (1 in each HCT group). No ZV HT recipient had a rash that was PCR positive for the vaccine strain of VZV.
Background: Herpes zoster incidence is higher in patients with a hematopoietic stem cell transplant [HCT] (200 cases/1000 person-years) than in the general population (3-5 cases/1000 person-years). A heat-treated zoster vaccine [ZV HT ] was assessed in adults with allogeneic or autologous HCT. Methods: Randomized, double-blind, placebo-controlled, multicenter Phase I study of a 4-dose ZV HT regimen (1 dose pre-HCT; 3 doses post-HCT, each 30 days apart) in adults $ 18 years with autologous (n 5 50) or allogeneic (n 5 50) HCT. In each group, 40 received ZV HT and 10 placebo (Pbo). Blood was collected at baseline & 28 days after each dose to measure (1) VZV antibody concentrations by glycoprotein enzyme-linked immunosorbent assay (gpELISA), and (2) varicella zoster virus (VZV) T-cell responses by interferon-gamma enzyme-linked immunospot (IFN-g ELI-SPOT) assay. All vaccinated patients were evaluated for adverse events (AEs) through day 28 postdose 4. Immunogenicity analyses for both HCT groups were exploratory (no pre-specified hypotheses). Results: ZV HT safety profile was similar to placebo. Injection-site adverse events (AEs) occurred in 15% of the ZV HT group and 10% of the Pbo group. There were no reported vaccine-related serious AEs. No patients discontinued due to vaccine-related AEs. Herpes zoster (PCR positive) occurred in 1 ZV HT and 1 placebo patient (both autologous HCT patients). There were also 2 patients in the ZV HT group that had suspected HZ not confirmed by PCR (1 in each HCT group). No ZV HT recipient had a rash that was PCR positive for the vaccine strain of VZV.
At baseline, the VZV-specific gpELISA geometric mean titer (GMT) was 152 (90% CI: 107, 216) were hypermetabolic. Hypermetabolism occurred in 14/15 (93%) patients with FTT, while only 4/11 (36%) patients without FTT had hypermetabolism (P 5 0.003). There was a significant difference between the MREE (455 6 169 kcal) and the PREE (333 6 106 kcal) (p \ 0.0001). Hypermetabolism was significantly more common in those between the ages of 3-12 months. Logistic regression was performed to determine the probability of FTT using the MREE expressed as a percentage of the PREE for age and gender, adjusted for diarrhea and pneumonia. An increased probability of FTT was found, if hypermetabolism was present, independent of diarrhea and pneumonia. Eleven of 17 (65%) patients required nasogastric feeding and/or parenteral nutrition to meet their energy needs. Conclusions: Hypermetabolism is common in patients with SCID in the pre-BMT period and may contribute to the development of FTT. The hypermetabolism in these patients may necessitate intensive nutrition support. Cytomegalovirus (CMV) infections are associated with significant morbidity and mortality in the stem cell transplant setting. CMX001, a lipid conjugate of cidofovir is administered orally and circulates as the lipid conjugate in plasma; it is efficiently taken up by target cells and high concentrations of the active antiviral are achieved intracellularly. We describe the first clinical experiences in stem cell transplant patients infected with CMV who received CMX001. The patients had history of AML (3 patients), refractory lymphoma, multiple myeloma, and severe aplastic anemia, and sickle cell anemia. Six of the seven patients had received SCT and the seventh awaited SCT. Treatment with CMX001 was [n] Response (90%CI)
EXPERIENCE WITH CMX001, A NOVEL ANTIVIRAL DRUG, FOR CYTO-MEGALOVIRUS INFECTIONS IN STEM CELL TRANSPLANT PATIENTS
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